The clearance for the Monarch platform to be used in endourological procedures is just the news Johnson & Johnson's robotic-assisted-system program needed.

Omar Ford

May 4, 2022

2 Min Read
IMG_2022-5-4-162348.jpg
Image courtesy of Kristoffer Tripplaar / Alamy Stock Photo

Ethicon, a Johnson & Johnson MedTech company, announced news that should bring back some much-needed attention to its robotic-assisted-system program. Through its Auris Health subsidiary, Ethicon said it won FDA clearance for the Monarch platform to be used in endourological procedures.

Ethicon said the clearance makes Monarch the first and only multispecialty, flexible robotic solution for use in both bronchoscopy and urology.

“This latest FDA 510(k) clearance for Monarch delivers on our vision to extend the robotic platform’s capabilities across multiple specialties, enabling hospital systems to target two disease states using one device,” said Vladimir Makatsaria, Company Group Chairman, Ethicon.

Following this clearance, Ethicon said it expects to initiate a first-in-human clinical study later this year for the Monarch’s Platform’s endourologic application. 

J&J and Ethicon picked up Auris Health for $3.4 billion. It was arguably one of the biggest medtech deals of 2019. The acquisition also fueled J&J’s ambitions of becoming a robotic-assisted surgical powerhouse.

Those ambitions were brought to a fever pitch a few months after the Auris acquisition when J&J said it would acquire the remaining stake in Verb Surgical – a joint venture with Verily that would see the development of Ottava, a surgical robotics platform.

But the hype surrounding Ottava was cooled a bit when J&J announced in October of 2021 that the platform would be delayed by about two years. Developmental challenges that arose from the pandemic were listed as the culprits for the delay.

This move gave competitors like Medtronic, which had  won CE mark for its Hugo surgical robotics system a few days before J&J announced delaying Ottava, a much larger runway.

It even meant, for the time being, one less competitor for surgical robotics pioneer Intuitive Surgical to contend with.  The Sunnyvale, CA-based company has gone a little more than two decades without a larger competitor to its da Vinci Surgical robot in the space.

The delay also gives smaller players in the space like Vicarious Surgical and Memic Innovative Surgery the ability to gain significant ground. (Editor’s note: Memic recently mutually terminated its special purpose acquisition corporation merger with Medtech Acquisition Corps., citing unfavorable conditions.)

However, the Monarch clearance news is much needed for J&J’s surgical robotic plans. It shows that despite Ottava’s delay, the company is making progress in growing its often-touted surgical robotics ecosystem.

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like